Last reviewed · How we verify

Blood samples collect

Biocodex · Phase 3 active Biologic Under review

Blood samples collect is a Biologic drug developed by Biocodex. It is currently in Phase 3 development for Diagnosis and monitoring of various diseases, including infections, anemia, and other conditions.

Blood samples collection involves the process of obtaining and analyzing blood from patients to diagnose and monitor diseases.

Blood samples are collected for various studies, including those on healthy volunteers, anticoagulant therapy, hematopoietic cell transplantation, mucopolysaccharidosis type I, and HIV infections. The samples are typically collected as whole blood, which is defined by its composition of all blood components, including red blood cells, plasma, and other cellular elements.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameBlood samples collect
SponsorBiocodex
ModalityBiologic
Therapeutic areaDiagnostics
PhasePhase 3

Mechanism of action

This process typically involves drawing blood from a vein in the arm or other locations, and then analyzing the blood components to identify any abnormalities or changes that may indicate a disease or condition. The collected blood samples are then used to diagnose and monitor various diseases, including infections, anemia, and other conditions.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Blood samples collect

What is Blood samples collect?

Blood samples collect is a Biologic drug developed by Biocodex, indicated for Diagnosis and monitoring of various diseases, including infections, anemia, and other conditions.

How does Blood samples collect work?

Blood samples collection involves the process of obtaining and analyzing blood from patients to diagnose and monitor diseases.

What is Blood samples collect used for?

Blood samples collect is indicated for Diagnosis and monitoring of various diseases, including infections, anemia, and other conditions.

Who makes Blood samples collect?

Blood samples collect is developed by Biocodex (see full Biocodex pipeline at /company/biocodex).

What development phase is Blood samples collect in?

Blood samples collect is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing